[HTML][HTML] Loss of IRF-4–binding protein leads to the spontaneous development of systemic autoimmunity

JC Fanzo, W Yang, SY Jang, S Gupta… - The Journal of …, 2006 - Am Soc Clin Investig
JC Fanzo, W Yang, SY Jang, S Gupta, Q Chen, A Siddiq, S Greenberg, AB Pernis
The Journal of clinical investigation, 2006Am Soc Clin Investig
IFN regulatory factor 4–binding (IRF-4–binding) protein (IBP) is a novel type of activator of
Rho GTPases that is recruited to the immunological synapse upon TCR stimulation. Here we
demonstrate that loss of IBP leads to the spontaneous development of a systemic
autoimmune disorder characterized by the accumulation of effector/memory T cells and IgG+
B cells, profound hypergammaglobulinemia, and autoantibody production. Similar to human
SLE, this syndrome primarily affects females. T cells from IBP-deficient mice are resistant to …
IFN regulatory factor 4–binding (IRF-4–binding) protein (IBP) is a novel type of activator of Rho GTPases that is recruited to the immunological synapse upon TCR stimulation. Here we demonstrate that loss of IBP leads to the spontaneous development of a systemic autoimmune disorder characterized by the accumulation of effector/memory T cells and IgG+ B cells, profound hypergammaglobulinemia, and autoantibody production. Similar to human SLE, this syndrome primarily affects females. T cells from IBP-deficient mice are resistant to death in vitro as well as in vivo and exhibit selective defects in effector function. In the absence of IBP, T cells respond suboptimally to TCR engagement, as demonstrated by diminished ERK1/2 activation, decreased c-Fos induction, impaired immunological synapse formation, and defective actin polymerization. Transduction of IBP-deficient T cells with a WT IBP protein, but not with an IBP mutant lacking the Dbl-like domain required for Rho GTPase activation, rescues the cytoskeletal defects exhibited by these cells. Collectively, these findings indicate that IBP, a novel regulator of Rho GTPases, is required for optimal T cell effector function, lymphocyte homeostasis, and the prevention of systemic autoimmunity.
The Journal of Clinical Investigation